0001209191-18-016866.txt : 20180305 0001209191-18-016866.hdr.sgml : 20180305 20180305183940 ACCESSION NUMBER: 0001209191-18-016866 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180301 FILED AS OF DATE: 20180305 DATE AS OF CHANGE: 20180305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Herberts Curt A. III CENTRAL INDEX KEY: 0001691262 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 18668052 MAIL ADDRESS: STREET 1: 501 CANAL BLVD. STREET 2: POINT RICHMOND TECH CENTER CITY: RICHMOND STATE: CA ZIP: 94804 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-03-01 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001691262 Herberts Curt A. III C/O SANGAMO THERAPEUTICS, INC. POINT RICHMOND TECH CTR, 501 CANAL BLVD. RICHMOND CA 94804 0 1 0 0 Sr.VP & Chief Business Officer Common Stock 2018-03-01 4 M 0 171 12.12 A 14796 D Common Stock 2018-03-01 4 M 0 1430 9.41 A 16226 D Common Stock 2018-03-01 4 M 0 8087 14.07 A 24313 D Common Stock 2018-03-01 4 M 0 5312 3.50 A 29625 D Common Stock 2018-03-01 4 S 0 15000 23.0574 D 14625 D Stock Option (Right to Buy) 12.12 2018-03-01 4 M 0 171 0.00 D 2023-12-11 Common Stock 171 0 D Stock Option (Right to Buy) 14.07 2018-03-01 4 M 0 8087 0.00 D 2024-12-10 Common Stock 8087 11913 D Stock Option (Right to Buy) 9.41 2018-03-01 4 M 0 1430 0.00 D 2025-12-07 Common Stock 1430 17320 D Stock Option (Right to Buy) 3.50 2018-03-01 4 M 0 5312 0.00 D 2027-01-25 Common Stock 5312 54688 D All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017. The price reported is a weighted average price. The shares were sold at prices ranging from $22.60 to $23.60 The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Includes (a) 8,375 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date; and (b) 6,250 shares subject to restricted stock units granted on December 8, 2015 that will vest on December 8, 2018, subject to the Reporting Person's continued service with the Issuer through such date. Fully vested and exercisable. One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 11, 2014 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 8, 2015 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. The stock option vested and became exercisable for 25% of the shares upon the Reporting Person's completion of one year of service measured from the January 26, 2017 grant date, and the balance of the shares will vest and become exercisable in 36 successive equal monthly installments upon his completion of each additional month of service thereafter. /s/ Denise Winn, Attorney-in-Fact 2018-03-05